Symbol not found
:ADMS
Debt Financing / Related
Adamas Pharmaceuticals Says Amended Terms Of Royalty-Backed Loan Agreement With Healthcare Royalty Partners Extend Maturity Date To March 31, 2027
Published: 12/02/2020 12:28 GMT
(ADMS) - Adamas Announces Agreement to Amend Royalty-backed Loan Agreement With Healthcare Royalty Partners.
Adamas Pharmaceuticals Inc - Agreement Eliminated Potential Royalty Rate Step-up to 17.5%.
Adamas Pharmaceuticals - Amended Terms of Royalty-backed Loan Agreement With Healthcare Royalty Partners Extend Maturity Date to March 31, 2027.
Adamas Pharmaceuticals Inc - Amendment Will Come Into Effect Upon Closing Acquisition of Osmolex Er in Early 2021.
Adamas - Amended Terms of Deal With Hcr Also Added Covenant Requiring Co to Maintain a Minimum Cash, Investments Balance of $25 Million.
Adamas Pharmaceuticals Inc - Agreement Eliminated Potential Royalty Rate Step-up to 17.5%.
Adamas Pharmaceuticals - Amended Terms of Royalty-backed Loan Agreement With Healthcare Royalty Partners Extend Maturity Date to March 31, 2027.
Adamas Pharmaceuticals Inc - Amendment Will Come Into Effect Upon Closing Acquisition of Osmolex Er in Early 2021.
Adamas - Amended Terms of Deal With Hcr Also Added Covenant Requiring Co to Maintain a Minimum Cash, Investments Balance of $25 Million.